Indaptus Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Junyi Dai
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3 Columbus Circle New York City NY United States of America 10019
- IPO Date
- Aug 4, 2015
- CIK
- 0001857044
- Website
- indaptusrx.com
- Similar Companies
- Business
- Indaptus Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative immunotherapy products for oncology and infectious diseases. The company's primary therapeutic candidate, Decoy20, is currently undergoing a Phase 1b/2 clinical study, evaluating both its single-agent effects and its efficacy in combination therapy with the PD-1 checkpoint inhibitor, tislelizumab. This novel approach leverages specially engineered, non-pathogenic gram-negative bacteria to broadly activate innate and adaptive immune responses within the body. Decoy20 aims to provide durable responses for various cancers, including lymphoma, hepatocellular, colorectal, and pancreatic tumors, alongside chronic hepatitis B virus and human immunodeficiency virus infections. Recent developments include the dosing of the first patient in the combination trial and the completion of a safety lead-in, which indicated tolerability. The company, which was incorporated in 2021 and is headquartered in New York, New York, conducted a reverse stock split in June 2025 and secured recent financing to support its pipeline advancement.
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Comparing Indaptus Therapeutics (NASDAQ:INDP) & Aldeyra Therapeutics (NASDAQ:ALDX)
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Critical Review: Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP)
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics Announces Reverse Stock Split
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update